<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230216</url>
  </required_header>
  <id_info>
    <org_study_id>C464</org_study_id>
    <nct_id>NCT01230216</nct_id>
  </id_info>
  <brief_title>Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound</brief_title>
  <acronym>PREVUS</acronym>
  <official_title>Effect of Intensive Blood Pressure Control on Progression of Coronary Atherosclerosis: Randomized Evaluation by Intravascular Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of intensive blood pressure control
      compared to standard blood pressure control on progression of coronary atherosclerosis by
      intravascular ultrasound in hypertensive patients with coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antihypertensive therapy is reported to reduce cardiovascular events in patients with
      coronary artery disease. The goal of blood pressure in patients with coronary artery disease
      is recommended to control below 140/90mmHg. However, the effect of intensive blood pressure
      control compared to standard blood pressure control is still unknown. The purpose of this
      study is to evaluate the effect of intensive blood pressure control compared to standard
      blood pressure control on progression of coronary atherosclerosis by intravascular ultrasound
      in hypertensive patients with coronary atherosclerosis after 18 months. The goal of systolic
      blood pressure is under 120mmHg in intensive blood pressure control group and under 140mmHg
      in standard blood pressure control group. The design of this study is randomized control
      study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow patients enrollment
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of percent atheroma volume</measure>
    <time_frame>1.5-year</time_frame>
    <description>change of percent atheroma volume measured by intravascular ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause death</measure>
    <time_frame>1.5-year</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1.5-year</time_frame>
    <description>Death from cardiac diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular death</measure>
    <time_frame>1.5-year</time_frame>
    <description>Death from cardiovascular diseases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>1.5-year</time_frame>
    <description>myocardial infarction defined by ARC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>1.5-year</time_frame>
    <description>both ischemic and hemorrhagic strokes excluding transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>1.5-year</time_frame>
    <description>target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any coronary revascularization</measure>
    <time_frame>1.5-year</time_frame>
    <description>any coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization due to angina pectoris</measure>
    <time_frame>1.5-year</time_frame>
    <description>hospitalization due to angina pectoris</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization due to heart failure</measure>
    <time_frame>1.5-year</time_frame>
    <description>hospitalization due to heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of total atheroma volume</measure>
    <time_frame>1.5-year</time_frame>
    <description>change of total atheroma volume measured by intravascular ultrasond</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change of total atheroma volume</measure>
    <time_frame>1.5-year</time_frame>
    <description>percent change of total atheroma volume measured by intravascular ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of atheroma volume at most severe 10mm lesion</measure>
    <time_frame>1.5-year</time_frame>
    <description>change of atheroma volume at most severe 10mm lesion measured by intravascular ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>intensive blood pressure control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systolic blood pressure less than 120 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard blood pressure control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systolic blood pressure less than 140 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control systolic blood pressure less than 120 mmHg</intervention_name>
    <description>use losartan to control blood pressure</description>
    <arm_group_label>intensive blood pressure control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control systolic blood pressure less than 140 mmHg</intervention_name>
    <description>use losartan to control blood pressure</description>
    <arm_group_label>standard blood pressure control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery diseases which require coronary angiography or percutaneous coronary
             intervention

          -  primary hypertension (systolic blood pressure 140-180mmHg within one month)

        Exclusion Criteria:

          -  severe hypertension

          -  secondary hypertension

          -  treated with more than three antihypertensive drugs

          -  left main trunk trunk coronary artery disease

          -  moderate heart failure

          -  severe valvular disease

          -  liver dysfunction renal dysfunction (Cr&gt;=2.0mg/dl) Pregnant or nursing women severe
             arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>6066-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

